Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Memorial Sloan Kettering Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1884-01-01

Employees: 10K

Market Cap: -

Website: http://www.mskcc.org

Clinical Trials

A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib

Phase 1

Completed

Conditions: Lung Cancer
Recurrent Lung Adenocarcinoma
Lung Adenocarcinoma
Lung Cancer Metastatic
Lung Cancer Stage IV
Recurrent Lung Cancer

Interventions: Drug: Trametinib
Drug: Erlotinib

First Posted Date: 2017-03-10

Last Posted Date: 2024-04-02

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 24

Registration Number: NCT03076164

Locations: 🇺🇸
Memorial Sloan Kettering Commack, Commack, New York, United States
🇺🇸
Memoral Sloan Kettering Cancer Center, Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

and more 4 locations

A Clinical Study to Test the Effects of Ruxolitinib And Thalidomide Combination for Patients With Myelofibrosis

Phase 2

Active, not recruiting

Conditions: Myelofibrosis

Interventions: Drug: Ruxolitinib
Drug: Thalidomide

First Posted Date: 2017-03-03

Last Posted Date: 2025-03-04

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 30

Registration Number: NCT03069326

Locations: 🇺🇸
Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Commack, Commack, New York, United States
🇺🇸
Memorial Sloan Kettering Westchester, Harrison, New York, United States

and more 4 locations

A Study of Talimogene Laherparepvec (T-VEC) in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma

Phase 2

Active, not recruiting

Conditions: Sarcoma
Epithelioid Sarcoma
Cutaneous Angiosarcoma

Interventions: Drug: Talimogene Laherparepvec (T-VEC)
Drug: Pembrolizumab

First Posted Date: 2017-03-03

Last Posted Date: 2025-04-02

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 41

Registration Number: NCT03069378

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
MD Anderson Cancer Center (Data Analysis Only), Houston, Texas, United States
🇺🇸
Enable Medicine (Specimen Analysis Only), Menlo Park, California, United States

and more 2 locations

Comparison of MRI and CEDM to Evaluate Treatment Response Before Surgery

Not Applicable

Completed

Conditions: Breast Cancer

Interventions: Diagnostic Test: Breast Magnetic Resonance Imaging (MRI)
Diagnostic Test: Contrast Enhanced Mammography (CEDM)

First Posted Date: 2017-03-03

Last Posted Date: 2023-11-21

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 125

Registration Number: NCT03070340

Locations: 🇺🇸
Memorial Sloan Kettering Basking Ridge (Consent only), Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Bergen (Consent only), Montvale, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Commack (Consent only), Commack, New York, United States

and more 2 locations

Study of Chemotherapy With or Without Hepatic Arterial Infusion for Patients With Unresectable Metastatic Colorectal Cancer to the Liver

Phase 2

Withdrawn

Conditions: Colorectal Adenocarcinoma Metastatic to the Liver

Interventions: Drug: Floxuridine (FUDR)
Drug: Irinotecan (CPT-11)
Drug: FLUOROURACIL
Drug: PANITUMUMAB
Drug: DEXAMETHASONE
Drug: Leucovorin

First Posted Date: 2017-03-03

Last Posted Date: 2019-05-21

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Registration Number: NCT03069950

Locations: 🇺🇸
Memorial Sloan Kettering Commack, Commack, New York, United States
🇺🇸
Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸
Memoral Sloan Kettering Westchester, Harrison, New York, United States

and more 2 locations

BCMA Targeted CAR T Cells With or Without Lenalidomide for the Treatment of Multiple Myeloma

Phase 1

Active, not recruiting

Conditions: Multiple Myeloma

Interventions: Biological: EGFRt/BCMA-41BBz CAR T cell
Drug: Cyclophosphamide
Drug: Lenalidomide.

First Posted Date: 2017-03-03

Last Posted Date: 2025-04-02

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 20

Registration Number: NCT03070327

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

A Study of LEE011 With Everolimus in Patients With Advanced Neuroendocrine Tumors

Phase 2

Completed

Conditions: Neuroendocrine Tumors

Interventions: Drug: LEE011
Drug: everolimus

First Posted Date: 2017-03-03

Last Posted Date: 2024-10-10

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 21

Registration Number: NCT03070301

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Md Anderson Cancer Center, Houston, Texas, United States

and more 2 locations

Trial of ADT and SBRT Versus SBRT for Intermediate Prostate Cancer

Phase 3

Terminated

Conditions: Prostate Cancer

Interventions: Drug: Degarelix
Radiation: stereotactic body radiosurgery (SBRT)

First Posted Date: 2017-02-17

Last Posted Date: 2024-08-28

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 56

Registration Number: NCT03056638

Locations: 🇺🇸
Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States

and more 7 locations

Investigation of the Effects of Electronic Cigarettes on Vascular Health

Not Applicable

Terminated

Conditions: Vascular Health

Interventions: Behavioral: Electronic cigarette
Behavioral: (sham cigarette) - no actual exposure to cigarettes
Behavioral: traditional cigarette

First Posted Date: 2017-02-02

Last Posted Date: 2021-06-18

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 12

Registration Number: NCT03041493

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Assessing How Normal Variations in CT Scanning Affects Its Interpretation

Active, not recruiting

Conditions: Colorectal Cancer Metastatic

Interventions: Diagnostic Test: CT scan

First Posted Date: 2017-01-31

Last Posted Date: 2025-04-23

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 169

Registration Number: NCT03038568

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
MD Anderson Cancer Center, Texas (Data collection only), Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy